8 results for "Spiro, Timothy"
Showing 1–8 · 0.27 seconds · RSS
-
Journal Article Full text
Haematuria as an uncommon initial presenting symptom of metastatic squamous cell carcinoma (SCC) to kidney
A 47-year-old female presented with a 2-week history of painless haematuria. Urine dipstick showed moderate leucocytes. Blood and urine cultures were negative and cytology was negative for malignant cells. Flexible cystoscopy was negative for any bladder pathology. An ultrasonogram of the abdomen…
-
Journal Article Full text
BOOP as a rare complication of gemcitabine therapy
Gemcitabine is commonly used in combination with carboplatin in patients with advanced non-small-cell lung cancer (NSCLC). Gemcitabine has good clinical activity against NSCLC and is well tolerated by the patients. Myelosuppression is its dose-limiting toxicity. A potential side effect of…
-
Journal Article Full text
Management of Atrial Fibrillation in Patients on Ibrutinib: A Cleveland Clinic Experience
Background Ibrutinib is a Bruton’s tyrosine kinase inhibitor, which is United States Food and Drug Administration (FDA)-approved for chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström’s macroglobulinemia. Ibrutinib is associated with atrial fibrillation and bleeding events. Our aim…
-
Journal Article Full text
5-Fluorouracil–Induced Cardiotoxicity During Chemotherapy for Adenocarcinoma of the Small Bowel
-
Journal Article Full text
Dosage Adjustments for Chemotherapy and Targeted Therapies in Colorectal and Pancreatic Cancer Patients with Hepatic Impairment
There are many novel chemotherapeutic options and targeted therapies available for the treatment of colorectal and pancreatic cancer. Patients with these cancers often have hepatic impairment either from the metastasis to the liver or from the chemotherapy or targeted therapies used to treat the…
-
Journal Article Full text
Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects
Since sodium stibogluconate (SSG) inhibited phosphatases including SHP-1 and augmented anti-tumor actions of IFN-α2b in vitro and in mice, two Phase I trials of SSG/IFN-α2b combination were undertaken to evaluate safety and target inhibition. Escalating doses of SSG (200-1200 mg/m(2)) and fixed…
-
Journal Article Full text
Metaplastic Breast Cancer: Characteristics and Survival Outcomes
Objectives Metaplastic breast cancer (MBC) is a rare neoplasm accounting for